Metsera, a biotechnology start-up company, has raised $215 million in a Series B funding round, which it plans to use to support the continued development of its range of obesity treatments. In particular the company will focus on: the long-acting GLP-1 drug, MET-097i; injectable amylin analog, MET-233i; and oral GLP-1 peptide, MET-002, with plans to explore combination therapies.

To date, the company has raised funds of over $500 million and has partnered with Amneal Pharmaceuticals. It intends to invest a portion of these funds into the expansion of manufacturing capabilities, including the construction of two new production sites.